NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
NTHICALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc’s drug discovery engine and helps accelerate its mission to develop therapies for complex neurological cancers.
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
NTHICALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones.
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
NTHICALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company’s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial.
NeOnc Technologies Says USC Brain Tumor Authority To Accelerate Four Clinical Trials Including Lead Asset NEO100 Nearing Phase 2a Completion Ahead Of Schedule
NTHINeOnc Technologies Names Josh Neman CCO; Says Appointment Bolsters FDA Approval Path While Company Explores AI And Quantum Computing To Enhance Drug Delivery Platform
NTHINeonc Technologies Expects Full Enrollment In Phase 2a Clinical Trial For Lead Therapeutic Candidate, NEO100-01 In September
NTHINeOnc Technologies Holdings Appoints Executive Chairman Amir Heshmatpour As Company's New President
NTHINeOnc Technologies Holdings Announces Phase I Clinical Trial of NEO212 For Brain Cancer Nearing Full Enrollment.
NTHINeOnc Technologies Receives Rare Pediatric Disease Designation For NEO100 In Treatment Of Pediatric-Type Diffuse High-Grade Gliomas
NTHI